Transplantation Proceedings
Volume 39, Issue 8 , Pages 2501-2506, October 2007

Dual Effect of Nitrate Therapy for Cyclosporine-Induced Hypertension on Vascular and Platelet Morphofunctional Markers; An Animal Model

  • F. Reis

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
  • ,
  • E. Teixeira de Lemos

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • Corresponding Author InformationAddress reprint requests to Prof Frederico Teixeira, Therapeutics Unit, Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, 3004-504 Coimbra, Portugal.
  • ,
  • L. Almeida

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
  • ,
  • B. Parada

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
  • ,
  • A.P. Garrido

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
  • ,
  • P. Rocha-Pereira

      Affiliations

    • Chemistry Department, Beira Interior University, Covilhã, Portugal
    • Molecular and Cellular Biology Institute, Porto University, Porto, Portugal
  • ,
  • A. Santos-Silva

      Affiliations

    • Biochemistry Service, Faculty of Pharmacy, Porto University, Porto, Portugal
    • Molecular and Cellular Biology Institute, Porto University, Porto, Portugal
  • ,
  • J. Santos-Dias

      Affiliations

    • Electron Microscopy Laboratory, Botanic Department, Faculty of Science and Technology, Coimbra University, Coimbra, Portugal.
  • ,
  • A. Dinis

      Affiliations

    • Electron Microscopy Laboratory, Botanic Department, Faculty of Science and Technology, Coimbra University, Coimbra, Portugal.
  • ,
  • A. Figueiredo

      Affiliations

    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
  • ,
  • C. Costa-Almeida

      Affiliations

    • Institute of Physiology, Faculty of Medicine, Coimbra University, Coimbra, Portugal
  • ,
  • A. Mota

      Affiliations

    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
  • ,
  • F. Teixeira

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal

Abstract 

The present study sought to evaluate the prevention and reversion effects of isosorbide-5-mononitrate (Is-5-Mn) on the development of hypertension (HT) and on the underlying vascular and platelet morphofunctional disturbances, using an animal model of cyclosporine (CsA)-induced HT. The following rat groups (n = 8) were tested: (1) a control group (orange juice, for 7 weeks); (2) the CsA group (5 mg/kg/d for 7 weeks); (3) the Is-5-Mn group (150 mg/kg/d, twice a day for 7 weeks); (4) the prevention group (Is-5-Mn + CsA) treated for 2 weeks with Is-5-Mn only and thereafter with both drugs for 7 weeks; (5) the curative group (CsA + Is-5-Mn) beginning 7 weeks after CsA and following thereafter with both drugs for 5 weeks. Blood pressure, lipid profile, vascular lesion, platelet aggregation and morphology, and platelet thromboxane A2/vascular prostacyclin equilibrium were evaluated. Is-5-Mn + CsA therapy prevented (systolic blood pressure [SBP]: 114.3 ± 1.9 mm Hg, P < .001; diastolic blood pressure [DBP]: 97.0 ± 3.3 mm Hg, P < .001) the CsA-induced HT (SBP: 146.2 ± 4.5 mm Hg, P < .001; DBP: 124.9 ± 4.5 mm Hg, P < .001 vs control: SBP: 111.6 ± 0.7 mm Hg; DBP: 94.6 ± 1.0 mm Hg), as well as the vascular lesion and the platelet morphofunctional disturbances. The curative group did not show attenuated CsA-induced BP increase; it showed further enhancement of the HT effect (SBP: 159.7 ± 5.5 mm Hg, P < .05; DBP: 132.8 ± 2.8 mm Hg), as well as worsened vascular lesions and platelet function, namely a disruption in the TXA2/PGI2 equilibrium. Our data suggested that Is-5-Mn therapy may be a valid choice to prevent the morphofunctional changes associated with CsA-induced HT, when used as a preventive therapy. A careful evaluation of the impact of nitrate therapy should be considered, particularly the negative effect on cardiovascular hemodynamics, when considering its use after previous CsA disturbances have been established.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0041-1345(07)00864-0

doi:10.1016/j.transproceed.2007.07.029

Transplantation Proceedings
Volume 39, Issue 8 , Pages 2501-2506, October 2007